So funny. You said "than" instead of "then" in your thread title. It made me generate preconceived notions that you are below average intelligence. Then I actually read the content of your post.
It confirmed my impressions.
Have an awesome day!
lol, you are in love with that guy.
Its possible that an institutional investor is buying again. Notice that the bashers are back today? Manipulate it down and accumulate. Thats the likely scenario.
You are incorrect - the 2M pound grant was from Innovate UK. The information I'm posting about is an actual Phase2a study collaboration.
You can find the link to info by searching signalsblogDOTca or by searching for Mark Curtis at Centre for Commercialization of Regenerative Medicine (CCRM)
This is close, and even if the low assumptions you have end up being true, it was stated on conference call that after they hired consulting agency to evaluate the insurance reimbursement, they expected to get at a minimum 50% of the market. That's a LOW estimate. They will probably get close to 75% of the market because there are no other approved treatments available. That means using your evaluation they'd be over $150 a share.
BUT - and this is what the guy who was going bananas posting at me today isn't calculating, thats only if you are putting as value on the stroke indication. THEY HAVE OTHER TRIALS AND OTHER INDICATIONS THEY ARE GOING AFTER. Positive stroke data validates the whole platform. Also, their Intellectual property, their real estate, their cash on hand, theri existing licensing deals (and new ones to come), AND the pure specualtive nature of people over paying for the shares will drive this to $200.
I dont care what the other people post. I'm right.
lol - you dont seem like you are having any fun. I'm having an awesome time! The ignore button is right there next to my name...do it...you'll feel better!
$200 by April. Have an awesome day!